UK markets open in 7 hours 56 minutes

Ocular Therapeutix, Inc. (OCUL)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
5.80-0.37 (-6.00%)
At close: 04:00PM EDT
5.80 -0.00 (-0.05%)
After hours: 06:27PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close6.17
Open5.97
Bid5.79 x 1600
Ask5.82 x 800
Day's range5.57 - 6.30
52-week range2.00 - 11.31
Volume5,656,458
Avg. volume2,650,026
Market cap897.411M
Beta (5Y monthly)1.32
PE ratio (TTM)N/A
EPS (TTM)-1.02
Earnings date07 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est15.50
  • GlobeNewswire

    Ocular Therapeutix™ to Present at Two Upcoming Investor Conferences

    BEDFORD, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye, today announced that it will participate at two investor conferences in May: Citizens JMP Life Sciences Confe

  • GlobeNewswire

    Ocular Therapeutix™ To Present at Two Ophthalmology Meetings, May 4-9, 2024

    2024 OIS Retina and ARVO meetings are being held in Seattle, WashingtonBEDFORD, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye, announced multiple presentations at th

  • GlobeNewswire

    Ocular Therapeutix™ to Host Investor Day in New York City on Thursday, June 13, 2024

    First quarter 2024 financial results to be reported on Tuesday, May 7, 2024 Investor Day to replace first quarter 2024 earnings conference call; quarterly calls to resume regular cadence with second quarter 2024 financial results BEDFORD, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative therapies